Table 1.
Demographic background of enrolled patients
| Item | Unit | N | Mean | ±SD |
|---|---|---|---|---|
| Sex | ||||
| Male | Number | 1 | – | – |
| Female | Number | 29 | – | – |
| Age | Years old | 30 | 78.1 | 7.2 |
| Body weight | kg | 30 | 53.2 | 10.9 |
| Patient: previously treated with BP | Number | 1 | – | – |
| Patient: prevalent vertebral fractures at baseline | Number | 21 | – | – |
| T-score at the start of Dmab administration | ||||
| Lumbar vertebra | SD | 22 | − 2.8 | 0.9 |
| Femoral neck | SD | 24 | − 3.2 | 0.8 |
| TRACP-5b at the start of Dmab administration | mU/dL | 28 | 551.4 | 261.2 |
| P1NP at the start of Dmab administration | ng/mL | 17 | 70.7 | 35.5 |
| Number of Dmab administration | Times | 30 | 3.1 | 1.6 |
| Days after changing Dmab to ZOL | Days | 30 | 277.8 | 75.0 |
Data are presented as mean ± SD
BP bisphosphonate, Dmab denosumab, P1NP total Type I procollagen N-terminal propeptide, TRACP-5b Tartrate Resistant Acid Phosphatase 5b, ZOL zoledronic acid